title: Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab.
abstract: Infliximab, a chimeric mouse-human monoclonal antibody, blocks the action of tumor necrosis factor-alpha and is a highly effective treatment for several inflammatory disorders, including inflammatory bowel disease and rheumatoid arthritis. Although safety data are encouraging, immunosuppressive sequelae may result. We report the acute development of multiple squamous cell carcinomas and keratoacanthomas in a patient receiving infliximab for rheumatoid arthritis.
authors.affiliation: Department of Dermatology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL 32224, USA.
authors.forename: Adam C
authors.initials: AC
authors.lastname: Esser
authors.forename: Andy
authors.initials: A
authors.lastname: Abril
authors.forename: Scott
authors.initials: S
authors.lastname: Fayne
authors.forename: John A
authors.initials: JA
authors.lastname: Doyle
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000009:adverse effects* / Q000276:immunology / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D002294:Carcinoma, Squamous Cell / Q000209:etiology* / Q000276:immunology; D005260:Female; D006801:Humans; D000069285:Infliximab; D007636:Keratoacanthoma / Q000209:etiology* / Q000276:immunology; D012878:Skin Neoplasms / Q000209:etiology* / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D000069285:Infliximab